Phase 1 N=357 Use of the VisuMax™ Femtosecond Laser
Myopia
Primary: Effectiveness- Predictability of Participant Refractive Outcomes — 291; 306 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AEs — 4; 12 Participants
Phase 1 N=6 Absorption & Elimination of Radiolabelled GSK2269557
Pulmonary Disease, Chronic Obstructive
Primary: Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0…
Phase 1 N=22 Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Number and Percent of Participants With Reduction of Immunity to Collagen Type-II After APLA-12 Treatment. — 9; 4 Participants — p=0.5179
Phase 1 N=190 Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 2743.2; 2503.3 h·μg/mL
Phase 1 N=15 A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-831 — 650.04; 865.48 nanogram per milliliter (ng/mL) — p=0.0058
Phase 1 N=6 Absorption and Elimination of Radiolabeled Daprodustat
Anaemia
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma…
Phase 1 N=150 Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
Pneumococcal Infections
Primary: Adult: Percentage of Participants With Any Adverse Event — 93.3; 83.3 Percentage of Participants
Phase 1 N=8 A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers
Gonorrhoea
Primary: Maximum Observed Concentration (Cmax) of Zoliflodacin — 20863 ng/mL
Phase 1 N=36 A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
Advanced Solid Tumors · Lymphomas
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) — 30 mg
Phase 1 N=10 Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Lymphoma, B-Cell
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 2 Participants
Phase 1 N=76 A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ) of LY2605541 and Insulin Glargine: Intra-Participant Variability…
Phase 1 N=40 Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot
Acute Heart Failure
Primary: Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events — 4; 9; 16; 11 participants
Phase 1 N=59 A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Advanced Malignancies
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Phase 1 N=39 A Phase 1 Study in Patients With Solid Tumors
Solid Tumors
Primary: Recommended Phase 2 Dose